Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8474294 | 0.85 | ALDH1A1 (0.49) | MDM2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL14434156 | 0.85 | ALDH1A1 (0.50) | CYP1A2CYP2C19MAPTALDH1A1MEN1 | |
| SCHEMBL15874277 | 0.82 | CHEK2 (0.43) | MAOBMAOAMAPTALDH1A1KMT2A | |
| Fluoride SCHEMBL8146479 | 0.80 | CYP1A2 (0.64) | CYP1A2CYP2C9CYP2C19MAOBIDO1 | |
| SCHEMBL29242 | 0.78 | CYP1A2 (0.67) | CYP1A2CYP2C9CYP2C19MAOBIDO1 | |
| SCHEMBL28180410 | 0.78 | CYP1A2 (0.67) | CYP1A2CYP2C9CYP2C19MAOBIDO1 | |
| SCHEMBL2724772 | 0.78 | CYP1A2 (0.67) | CYP1A2CYP2C9CYP2C19MAOBIDO1 | |
| SCHEMBL11320631 | 0.78 | CYP1A2 (0.67) | CYP1A2CYP2C9CYP2C19MAOBIDO1 | |
| SCHEMBL10506577 | 0.75 | CYP1A2 (0.64) | CYP1A2CYP2C9CYP2C19MAOBIDO1 | |
| SCHEMBL10506583 | 0.75 | CYP1A2 (0.64) | CYP1A2CYP2C9CYP2C19MAOBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110060005-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110060005-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-20100331363-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331363-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100160372-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160372-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| EP-1339709-B1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-24 | — | — | EP | disclosed |
| US-7253183-B2 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-07 | — | — | US | disclosed |
| US-6177432-B1 | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | JANSSEN-CILAG S.A. (FR) | 2001-01-23 | — | — | US | disclosed |
| US-6169096-B1 | FOR INHIBITING TUMOR GROWTH IN A MAMMAL | JANSSEN PHARMACAEUTIC N.V. (BE) | 2001-01-02 | — | — | US | disclosed |
| US-6150377-A | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. (US) | 2000-11-21 | — | — | US | disclosed |
| EP-0988038-A1 | (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-29 | — | — | EP | disclosed |
| US-6037350-A | USEFUL AS ANTICANCER AGENTS FOR TUMORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2000-03-14 | — | — | US | disclosed |
| EP-0977750-A1 | FARNESYLTRANSFERASE INHIBITING QUINAZOLINONES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998055124-A1 | (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-10 | — | — | WO | disclosed |
| WO-1998049157-A1 | FARNESYLTRANSFERASE INHIBITING QUINAZOLINONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-11-05 | — | — | WO | disclosed |
| EP-0865440-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997021701-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060005-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | NLN, FNTA, ACAT1 | CYP1A2 2134/4885CYP2C9 3312/4885CYP2C19 2397/4885 |
| US-20100160372-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | CYP1A2 3957/4885CYP2C9 4539/4885CYP2C19 4365/4885 |
| US-20100331363-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | NLN, ACAT1, FH | CYP1A2 1837/4885CYP2C9 2994/4885CYP2C19 2416/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | CYP1A2 3661/4885CYP2C9 4438/4885CYP2C19 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.